- Home
- PHAT vs CUB Comparison
PHAT vs CUB Comparison
Compare PHAT & CUB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- CUB
- Stock Information
- Founded
- PHAT 2018
- CUB 2024
- Country
- PHAT United States
- CUB United States
- Employees
- PHAT N/A
- CUB N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- CUB
- Sector
- PHAT Health Care
- CUB
- Exchange
- PHAT Nasdaq
- CUB NYSE
- Market Cap
- PHAT 289.0M
- CUB 320.5M
- IPO Year
- PHAT 2019
- CUB 2024
- Fundamental
- Price
- PHAT $4.25
- CUB $10.49
- Analyst Decision
- PHAT Strong Buy
- CUB
- Analyst Count
- PHAT 4
- CUB 0
- Target Price
- PHAT $16.25
- CUB N/A
- AVG Volume (30 Days)
- PHAT 2.2M
- CUB 91.0K
- Earning Date
- PHAT 05-01-2025
- CUB 05-13-2025
- Dividend Yield
- PHAT N/A
- CUB N/A
- EPS Growth
- PHAT N/A
- CUB N/A
- EPS
- PHAT N/A
- CUB 0.34
- Revenue
- PHAT $81,859,000.00
- CUB N/A
- Revenue This Year
- PHAT $195.45
- CUB N/A
- Revenue Next Year
- PHAT $106.76
- CUB N/A
- P/E Ratio
- PHAT N/A
- CUB $31.25
- Revenue Growth
- PHAT 3055.70
- CUB N/A
- 52 Week Low
- PHAT $2.21
- CUB $9.96
- 52 Week High
- PHAT $19.71
- CUB $10.55
- Technical
- Relative Strength Index (RSI)
- PHAT 54.83
- CUB N/A
- Support Level
- PHAT $3.92
- CUB N/A
- Resistance Level
- PHAT $4.35
- CUB N/A
- Average True Range (ATR)
- PHAT 0.40
- CUB 0.00
- MACD
- PHAT 0.13
- CUB 0.00
- Stochastic Oscillator
- PHAT 85.63
- CUB 0.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.